Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-05)
Sponsor: Ollin Biosciences, Inc.
Summary
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
Official title: A Phase 3, Randomized, Double-masked, Multicenter, Active Comparator-controlled Trial to Investigate the Efficacy and Safety of Monthly Intravitreal OLN324 in Adult Participants With Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
400
Start Date
2026-10-15
Completion Date
2029-12-15
Last Updated
2026-09-11
Healthy Volunteers
No
Conditions
Interventions
OLN324
OLN324 by intravitreal injection monthly
Ranibizumab
Ranibizumab by intravitreal injection monthly